Search company, investor...

Founded Year



Incubator/Accelerator | Alive

Total Raised


About Arti

Arti develops software helping embed content into augmented reality (AR) experiences. It creates the interface between the real and virtual worlds as a marker. It democratizes augmented reality (AR) for engaging video presentations, pitches, and stories. It was founded in 2019 and is based in Tel Aviv, Israel.

Headquarters Location

50 Harakevet

Tel Aviv,


+972 537177175


Arti's Product Videos

Arti's Products & Differentiators

    Arti AR

    Augmented reality software for creators


Expert Collections containing Arti

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arti is included in 1 Expert Collection, including AR/VR.



1,443 items

This collection includes companies creating hardware and/or software for augmented reality, virtual reality, and mixed reality applications.

Arti Patents

Arti has filed 3 patents.

The 3 most popular patent topics include:

  • babycare
  • child safety
  • infancy
patents chart

Application Date

Grant Date


Related Topics




Infancy, Pediatrics, Neonatology, Babycare, Child safety


Application Date


Grant Date



Related Topics

Infancy, Pediatrics, Neonatology, Babycare, Child safety



Latest Arti News

The Feasibility of C-Reactive Protein Point-of-Care Testing to Reduce Overuse of Antibiotics in Children with Acute Respiratory Tract Infections in Rural Kyrgyzstan: A Pilot Study

Feb 12, 2024

Inclusion Screening of patients took place in the waiting areas of the three participating medical facilities. A screening form was used to identify eligible patients according to inclusion and exclusion criteria. The screening form was in Russian (which is the official language of interethnic communication along with Kyrgyz, which is the state language in Kyrgyzstan). If the child’s caregiver desired, the researcher could translate the question into Kyrgyz to help if language difficulties arose. After verbal and written information, the informed consent was signed. All included children underwent a rapid test for SARS-CoV-2. If the test was positive, the child was withdrawn from the study and managed according to the present Kyrgyz guidelines for COVID-19. Randomisation If the test was negative, the child was randomised to intervention or control using the SealedEnvelope™ programme. 26 Children allocated to the intervention had a CRP POCT done during their consultation with a HCW and the result used as guidance for initiating or withholding antibiotic treatment. The randomised children fell into two groups: the intervention group – management based on the results of the CRP test, and the control group – usual care, as in daily practice before the intervention (ie, the doctor prescribes medicines without knowledge of CRP results, but based on the clinical picture). Data Collection The RA completed a case report form (CRF) for all included children during the consultation in collaboration with a HCW in their office. The CRF contained items on the child’s demographics, symptoms at the time of the consultation, physical examination results, treatment prescribed, and diagnosis. In addition, at the end of the CRF there were several questions to the HCWs and the caregivers of the child about their experience of accepting and working with the CRP POCT method, which was necessary for examining the feasibility. At the conclusion of the pilot study, a dedicated feasibility survey (as part of the CRF) was administered to all HCWs involved in the research. Additionally, caregivers also provided unsolicited feedback in this survey. Follow-Up 14 Days Follow-up was carried out through phone calls to the caregivers. Both groups were assessed on the 3rd, 7th, and 14th day by phone calls using follow-up questionnaires including questions on recovery and symptoms as well as complications or hospitalisations. The study procedure is shown in Figure 1 . Figure 1 The study procedure. Initially, prior to data collection, HCWs at selected medical centres are trained to use the CRP machine and interpret the results, after which children are screened for eligibility. The next step is obtaining informed consent from the child’s parent or caregiver, a rapid test for SARS-CoV-2, and a randomisation process. Then data is collected using the CRF, and then again on days 3, 7 and 14 by phone. Data Analysis This feasibility trial was not powered to detect statistically significant differences between groups. However, we analysed and calculated proportions of patient inclusion, antibiotic use, and follow-up rates to assist in optimal planning of the main trial. Results Pilot results A total of 192 children underwent screening during the pilot study period, of which 81 children were enrolled in the study. The last follow-up phone call was conducted on 31st of December 2021. One hundred and eleven children had one or more exclusion criteria with “taken an antibiotic 24 hours before the consultation” being the most common reason (n = 54). The enrolment is shown in Figure 2 at three different healthcare facilities. Forty children were randomised to intervention group and 41 children to control group. Six children (4 from intervention group and 2 from control group) were referred for hospitalisation during the index consultation, after the randomisation procedure, after being examined by a HCW (by decision of a local HCW). Baseline characteristics of included children, the commonest primary complaint as stated by caregivers, HCWs clinical diagnosis, CRP values of patients from the intervention group and antibiotics prescriptions in both groups are presented in Table 1 . Table 1 Baseline Characteristics, Group Allocation, CRP Values, and Antibiotics Prescriptions Figure 2 The enrolment tree. A total of 192 children were screened, of which 81 children were included in the study. 111 children for 1 or more criteria were excluded (of which 54 children were excluded because they took antibiotics 24 hours or less before screening). All included children had cough as the main complaint, as well as some other symptoms indicating ARTI. The commonest primary complaint as stated by caregivers was cough, while an unspecific viral infection. ARVI was the most frequent diagnosis by the HCWs. The CRP guidance reduced antibiotic prescriptions markedly (17% in intervention group vs 59% in control group). Most children had low CRP levels <10 mg/mL (29/40) and only 1/40 had a value above 50 mg/mL. In general, HCWs followed the protocol and prescribed antibiotics according to CRP levels in the intervention group. When the level of CRP <10, almost all HCWs (97.3%) did not prescribe antibiotics; however, there was still one HCW who prescribed antibiotics despite CRP - 8.9 (1 case). Follow-up and recovery: children were considered recovered when caregivers indicated in the follow-up questionnaire that their child was feeling better, well, or excellent (see Figure 3 ). The majority presented with infections that recovered well during the first week of follow-up. Children from both groups recovered successfully and equally in general well-being. Figure 3 Percentage of children in both groups who were considered recovered by their caregivers. In intervention group, on Day 3, according to parents or caregivers, 47% of children recovered, on Day 7–92%, and finally on Day 14–97%. In control group, parents or caregivers reported recovery on Day 3–49%, Day 7–87% and Day 14–90%. In terms of the data completeness, 71 children had all baseline assessment data and all follow-up data recorded (full data); 4 children had baseline data but no follow-up data. In hospitalised children allocated to the intervention group, the CRP values were 5.5, 20, 37, and 46. But at the decision of the research team, follow-up calls were also conducted to them. Follow-up assessments were done for 95% (n = 77) of children; for 4 children a baseline assessment had been conducted, but no follow-up data were obtained as caregivers had provided wrong phone numbers. Feasibility Results Based on a feasibility study conducted among all HCWs involved in the study at the conclusion of the pilot project, as well as among the parents or caregivers of children participating in the study, key opinions regarding the CRP POCT method were identified. When HCWs were asked about their general feelings about the use of the test, the majority responded very positively. Regarding the question about the convenience and practicality of implementing this test in their clinical practice, a majority answered “Definitely yes”. Similarly, when asked if they would like to use CRP POCT in their future practice, the majority once again responded “Definitely yes”. Only one out of eight HCWs answered “Do not know” to all three questions. Regarding the survey for parents and caregivers, there were only two questions: how they reacted to the use of CRP POCT to diagnose their children in general, and whether they consider it acceptable to use this test to diagnose children. The vast majority of responses were positive. Discussion Feasibility Findings HCWs viewed CRP as a simple and quick aid in diagnosis, and normal CRP levels were a strong argument for them to refrain from prescribing antibiotics. Local HCWs fully supported the introduction of this method into routine clinical practice based on their first experience with it and were positive about its use in the future. As for the attitude of caregivers to the CRP POCT method in relation to their children, their high willingness to accept this method in the daily clinical practice of health workers was noted, suggesting a high acceptability of this method could be expected in the main trial. With regard to their attitude towards the participation of their children in the study, in general, no incidents and opposition were noticed. A qualitative study in Lebanon on children’s participation in clinical trials found that Lebanese caregivers have similar perceptions and attitudes towards children’s participation in clinical trials as those reported in industrialised countries. 27 One qualitative study targeting the acceptability of the test among general practitioners reported that CRP POCT was acceptable to clinicians who believed in its usefulness and that CRP POCT, when used as an adjunct to clinical assessment, could be used to support efforts to counselling patients and improving decisions about prescribing antibiotics for ARTI. 28 The logistics of data collection worked as expected in the pilot. The completeness of data collection at the stage of follow-up calls was high. Four caregivers provided incorrect or no longer serviced phone numbers, leading to loss of follow-up. There are five mobile phone operators in Kyrgyzstan, 29 and many people have SIM cards from different operators; it may be wise to collect all phone numbers from the child’s caregiver and household. We estimate that the research model is quite suitable for a larger sample size in the main trial and will likely improve data completeness. Pilot Study Findings The pilot study showed that we could enrol roughly half of the screened patients; 81 children were enrolled in approximately two weeks (data collection in fields were conducted in period from 24th of November to 7th of December and the last follow-up phone call was conducted on 31st of December). In the upcoming main study, we plan to enrol 1204 children at 14 primary healthcare centres. According to the archival data of local medical institutions, the largest number of children with respiratory syndromes is observed in winter (December to March). It follows that the main study should also be done in winter to get the most patients in the least amount of time. The second finding is that children in the CRP POCT group were prescribed less antibiotics (17% as opposed to 59% in the control group). Given the small sample size of the pilot, the estimate must be interpreted with caution. Regardless, the finding is in line with a published meta-analysis summarising current data from 13 studies on the association between CRP POCT testing and antibiotic prescribing for ARTIs in general practice. CRP POCT testing has been found to significantly reduce antibiotic prescribing at the initial consultation. 30 This may generally speak in favour of confirming the effectiveness of this method, especially in conditions of low resources, when there are no other methods of laboratory or instrumental diagnostics at hand. 30–36 In terms of the primary outcomes, the recovery based on caregivers’ phone responses on Days 3, 7, and 14, overall recovery was similar in both groups. Naturally, we take into account that caregivers are not clinicians to assess the clinical or laboratory recovery of children, but they seem to do well in reporting subjective or objective indicators of recovery (general well-being of the child, body temperature, cough, shortness of breath, runny nose, etc). 37 It is worth paying attention to the fact that in both groups (A and B) a large proportion of the diagnosis of ARVI was made (40% in intervention group and 24.4% in control group, as well as laryngotracheitis 29.3% in control group, which can also be attributed to the manifestation of ARVI). That is, clinicians were aware that they diagnosed an infection of predominantly viral nature, but prescribed an antibiotic nevertheless. It is interesting that pneumonia was not particularly common and that most diagnoses recorded would normally not warrant antibiotic therapy. The low levels of CRP measured in the pilot support the notion that most cases of ARVI were likely self-limiting viral infections. These preliminary pilot data suggest that local HCWs are not entirely sure about the correctness of prescribing antibiotics for children with ARVI, highlighting the need for education and practical tools to assist in a more rational antibiotic use for children with ARVI. Furthermore, the study is likely safe to conduct in children, as no adverse events occurred during the pilot period. Conclusion This study was a pilot model before running a full-scale RCT. The pilot provided satisfactory results regarding both the effectiveness of the CRP algorithm as the CRP intervention group was prescribed markedly less antibiotic treatments as well as the feasibility of the study set up and associated procedures. Important issues to consider in the upcoming main trial include logistics and follow-up data from caregivers. Overall, we found both caregivers HCW to be interested in and comply with study requirements. Abbreviations ARTI, Acute respiratory tract infections; ARVI, Acute respiratory viral infections; COVID-19, coronavirus disease 2019; CRF, clinical report form; CRP, C-reactive protein; FMC, family medicine centre; FOP, feldscher-obstetrics point; FPG, family physicians group; HCW, healthcare workers; IMCI, integrated management of childhood illness; ISCRNT, international standard randomised controlled trial number; KAP, knowledge, attitudes and practices; LMIC, low- and middle-income countries; POCT, point-of-care test; RCT, randomised controlled clinical trial; SARS-CoV-2, severe acute respiratory syndrome-related coronavirus 2. Ethics The Ethical Committee of the National Centre of Maternity and Childhood Care of the Kyrgyzstan has approved the Study Protocol (Ref. no. 1. Date: 18/06/2021). The study participants are children living in the Kyrgyzstan, who are covered by the protection of citizens of the Kyrgyzstan. The trial will comply fully with all regulatory authorities and will be executed in accordance with Good Clinical Practice. Children in the CRP POCT arm are subjected to a finger prick causing minor transient pain. Acknowledgments The authors thank the University of Copenhagen library and authors of the included studies for providing full-text articles. The authors express their deep gratitude to the parents of the children who were sympathetic to the study and with great enthusiasm agreed to the participation of their children, as well as to the participants themselves for their courage and willingness to give their finger for analysis. Special thanks to the RAs, who travelled to rural medical facilities and collected data so carefully and diligently and who did all follow-up calls (Azat Bolotbek uulu, Nargiza Osmonbaeva, Aigerim Tilebalieva, Uuljan Bekbolsunova, Aichurok Alymbekova, Aiperi Muratova, Mohisitora Zhalalova, Zhamilya Zhumadilova). Funding This research was funded by the International Centre for Antimicrobial Resistance Solutions (ICARS) (grant number 100008) Copenhagen, Denmark, and Global Health Unit, Department of Paediatrics and Adolescent Health, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Disclosure References 1. van Gageldonk-Lafeber AB, van der Sande MAB, Heijnen MLA, Peeters MF, Bartelds AIM, Wilbrink B. Risk factors for acute respiratory tract infections in general practitioner patients in The Netherlands: a case-control study. BMC Infect Dis. 2007;7:1–8. doi:10.1186/1471-2334-7-35 2. Shalabayeva BS, Asheraliyev MY, Kabylova ET, Cherikchiyeva AB. Standardized approaches in the diagnosis and therapy of children with acute diseases of the respiratory and gastrointestinal tract in conditions of short-stay departments. Med J West Kazakhstan. 2018;3(59):34–39. 3. Hug L, Sharrow D, You DL. Trends in child mortality. New York; 2017. Available from: . Accessed . 4. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000 – 13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385:430–440. doi:10.1016/S0140-6736(14)61698-6 5. Nurmatov ZS. Assessment of the costs associated with outpatient and inpatient treatment of ARVI and influenza and its complications. Epidemiol Vaccinal Prev. 2015;14(5):26–30. doi:10.31631/2073-3046-2015-14-5-26-30 6. Nurmatov Z. Influenza and ARVI in Kyrgyzstan. Russ J Infect Immun. 2015;4:365–374. doi:10.15789/2220-7619-2014-4-365-374 7. Ibraimova A, Akkazieva B, Ibraimov A, Manzhieva E, Rechel B. Kyrgyzstan: health system review. Health Syst Transit. 2011;13:3. 8. World Health Organization. Regional Office for Europe and Policies, Health care systems in transition: Kyrgyzstan. Copenhagen PP - Copenhagen: World Health Organization. Regional Office for Europe; 2000. Available from: . Accessed . 12. Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15):E3463–E3470. doi:10.1073/pnas.1717295115 13. Baktygul K, Marat B, Ashirali Z, Harun-Or-rashid M, Sakamoto J. An assessment of antibiotics prescribed at the secondary health-care level in the Kyrgyz Republic. Nagoya J Med Sci. 2011;73(3–4):157–168. 14. Fridkin SK, Hageman J, McDougal LK, et al. Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis. 2003;36:429–439. doi:10.1086/346207 15. Long SW, Olsen RJ, Mehta SC, et al. PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2014;58:6668–6674. doi:10.1128/AAC.03622-14 16. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:1–11. doi:10.3389/fimmu.2018.00754 17. Bernstein D, Coster D, Berliner S, et al. C-reactive protein velocity discriminates between acute viral and bacterial infections in patients who present with relatively low CRP concentrations. BMC Infect Dis. 2021;21(1):1–7. doi:10.1186/s12879-021-06878-y 18. Lelubre C, Anselin S, Zouaoui Boudjeltia K, Biston P, Piagnerelli M. Interpretation of c-reactive protein concentrations in critically Ill patients. BioMed Res Int. 2013;2013:1–11. doi:10.1155/2013/124021 19. Smedemark SA, Aabenhus R, Llor C, Fournaise A, Olsen O, Jørgensen KJ. Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care. Cochrane Database Syst Rev. 2022;10(10):CD010130. doi:10.1002/14651858.CD010130.pub3 20. Cooke J, Llor C, Hopstaken R, Dryden M, Butler C. Respiratory tract infections (RTIs) in primary care: narrative review of C reactive protein (CRP) point-of-care testing (POCT) and antibacterial use in patients who present with symptoms of RTI. BMJ Open Respir Res. 2020;7:1. doi:10.1136/bmjresp-2020-000624 21. Wakeman M, Cork T, Watwood D. Point-of-care C-reactive protein testing in community pharmacy to deliver appropriate interventions in respiratory tract infections. Clin Pharm CP. 2018;10:5. doi:10.1211/PJ.2018.20204635 22. Martínez-González NA, Keizer E, Plate A, et al. Point-of-care C-reactive protein testing to reduce antibiotic prescribing for respiratory tract infections in primary care: systematic review and meta-analysis of randomised controlled trials. Antibiotics. 2020;9:9. doi:10.3390/antibiotics9090610 23. Althaus T, Greer RC, Swe MMM, et al. Effect of point-of-care C-reactive protein testing on antibiotic prescription in febrile patients attending primary care in Thailand and Myanmar: an open-label, randomised, controlled trial. Lancet Glob Heal. 2019;7(1):e119–e131. doi:10.1016/S2214-109X(18)30444-3 24. Samet JM, Wipfli H, Platz EA, Bhavsar N. A dictionary of epidemiology, fifth edition: edited by Miquel Porta. Am J Epidemiol. 2009;170(11):1449–1451. doi:10.1093/aje/kwp322 25. Isaeva E, Bloch J, Poulsen A, et al. C reactive protein-guided prescription of antibiotics for children under 12 years with respiratory symptoms in Kyrgyzstan: protocol for a randomised controlled clinical trial with 14 days follow-up. BMJ Open. 2023;13(4):e066806. doi:10.1136/bmjopen-2022-066806 26. Sealed Envelope Ltd. Simple randomisation service; 2022. Available from: . Accessed

Arti Frequently Asked Questions (FAQ)

  • When was Arti founded?

    Arti was founded in 2019.

  • Where is Arti's headquarters?

    Arti's headquarters is located at 50 Harakevet, Tel Aviv.

  • What is Arti's latest funding round?

    Arti's latest funding round is Incubator/Accelerator.

  • How much did Arti raise?

    Arti raised a total of $4M.

  • Who are the investors of Arti?

    Investors of Arti include Plug and Play Accelerator and Axon Ventures.

  • Who are Arti's competitors?

    Competitors of Arti include Kivisense and 4 more.

  • What products does Arti offer?

    Arti's products include Arti AR.


Compare Arti to Competitors

Modum Lab

Modum Lab specializes in digital solutions using virtual reality technology to enhance professional skills and productivity across various sectors. The company offers a range of VR/AR solutions for automating and improving business processes, corporate training, and education. Modum Lab primarily serves industries such as manufacturing, education, retail, e-commerce, and companies creating e-learning courses. It is based in St. Petersburg, Russian Federation.

Oculavis Logo

Oculavis is a company that focuses on developing Augmented Reality (AR) solutions for the mechanical engineering and manufacturing industry. The company's main service is a visual assistance software that connects machinery and equipment with experts, technicians, and customers worldwide, enabling remote collaboration and troubleshooting through AR annotations in video calls. The company primarily sells to the machinery and equipment manufacturing industry. It was founded in 2016 and is based in Aachen, Germany.

Augment IT Logo
Augment IT

Augment IT is a software company. It specializes in the development of mixed and augmented reality solutions. It also provides maintenance, training, and more services. The company was founded in 2017 and is based in Bern, Switzerland.

V-Cult Logo

V-Cult creates three-dimensional (3D) web, virtual reality (VR), and augmented reality (AR) solutions to enhance brand storytelling and boost business performance. It uses technologies to empower retail and product designers, brand educators, storytellers, and sales geniuses. The company was founded in 2009 and is based in Lille, France.

Kivisense Logo

Kivisense operates an online platform for website based augmented reality (WebAR). It offers an augmented reality (AR) engine supporting multiple AR or artificial intelligence (AI) algorithms. The platform was founded in 2018 and is based in Chengdu, China.

ViewAR Logo

ViewAR is a company focused on providing industrial augmented reality solutions, operating in the technology and software industry. The company's main offerings include augmented reality applications for indoor navigation, remote assistance, product visualization, and workflow management. These applications are primarily used in sectors such as manufacturing, retail, facility management, and education. It was founded in 2011 and is based in Vienna, Austria.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.